@Genkyotex_Off HYR 2020 and business update: cash of €5.1m at June 30, 2020 and a first patient enrolled in Phase 2 trial of setanaxib in IPF.More details here:

@Genkyotex_Off announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis.More details here:

@Genkyotex_Off announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA.More information here:

@Genkyotex_Off provides business update at June 30, 2020: Cash of €5.1m and ongoing discussions with US FDA and European EMA on the registration strategy for setanaxib in PBC.More details here:

@Genkyotex_Off announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib .More details here:

Genkyotex provides newclinical data from the PBC Phase 2 trial providing further evidence of the anti-fibrotic activityof setanaxib. More details here:

RT @UoSMedia: 🧪A new study by our @CCI_UoS @UoS_Medicine scientists makes a significant step towards more effective cancer immunotherapy tr….

@Genkyotex_Off: setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models.More details here:

@Genkyotex_Off : current cash reach to end of February 2021 and the Phase 2 study with setanaxib in IPF expected to start in the coming weeks.More details here :

@Genkyotex_Off raises €4.9m in its rights issue. The funds will finance its operations and help support the clinical development of setanaxib in multiple fibrotic indications.

#Genkyotex #PBC #GKT831.Previously reported data showed a 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supporting anti-fibrotic mechanism.

#Genkyotex #PBC #GKT831.GKT831 400mg BID demonstrated statistically significant improvements in GGT and ALP over full treatment period in our Ph2 trial in PBC (p<0.002 and p<0.001 respectively).

#GKTX #Genkyotex reports anti-fibrotic activity by #GKT831 in #Liver #Fibrosis Patients. Our results provide evidence for a potential breakthrough treatment in complex and difficult to treat fibrotic disorders like #NASH and #PSC.

#GKTX #Genkyotex reports clinical evidence of anti-fibrotic activity by #GKT831 in #Liver #Fibrosis patients .Conference call and webcast today at 1 pm CEST (in French) and at 2 pm CEST (in English).

#Genkyotex to present interim Ph2 efficacy data from GKT831 in #PBC at #EASL2019 International Liver Congress. GKT831 significantly reduced markers of cholestasis and inflammation after just 6 weeks. Top-line-24-week data expected this quarter #GKTX.

A great read for all those interested in NASH!.#NASH #NAFLD.

#GKT831 continued to demonstrate a favorable safety profile, supporting its anti-inflammatory / anti-fibrotic potential in multiple indications, such as #NASH, #IPF, diabetic nephropathy, scleroderma, and oncology.#Genkyotex #GKTX #PBC #Fibrosis .

#Genkyotex #GKTX announces completion of 24-week treatment period of its Ph2 trial in primary biliary cholangitis (#PBC), a fibrotic liver disease. #Genkyotex #GKTX #PBC #NASH #Fibrosis .

#GKTX #Genkyotex #PBC #GKT831 #Liver #FibrosisOver .85% of patients have completed the full 24-week treatment period in our Ph2 trial in PBC. No dropouts or treatment interruptions due to pruritus reported to date. Final results expected in Spring 2019.

#GKT831 #Genkyotex #GKTX GKT831 reduces tumor associated macrophage recruitment and suppresses tumor growth in non small cell lung cancer.